Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study.

Autor: Stockem CF; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Einerhand SMH; Department of surgical oncology (urology), The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rodríguez IM; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain., Salhi Y; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Pérez E; Department of Medical Oncology, Hospital Complex Insular-Materno Infantil, Las Palmas, Spain., Bakaloudi DR; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, USA., Talukder R; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, USA., Caramelo B; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain., Morales-Barrera R; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.; Universitat Autònoma de Barcelona, Bellaterra, Spain., De Meulenaere A; Department of Medical Oncology, Integrated Cancer Center, AZ Maria Middelares, Gent, Belgium., Rametta A; Oncologia Medica Genito-Urinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bottelli A; Oncologia Medica Genito-Urinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lefort F; Department of Medical Oncology, Hôspital Saint André-CHU de Bordeaux, Bordeaux, France., Giannatempo P; Oncologia Medica Genito-Urinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Vulsteke C; Department of Medical Oncology, Integrated Cancer Center, AZ Maria Middelares, Gent, Belgium.; Centre for Oncological Research (CORE), Antwerp University, Antwerp, Belgium., Carles J; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.; Universitat Autònoma de Barcelona, Bellaterra, Spain., Duran I; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain., Grivas P; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, USA.; Fred Hutchinson Cancer Center, Seattle, WA, USA., de Liaño AG; Department of Medical Oncology, Hospital Complex Insular-Materno Infantil, Las Palmas, Spain., Robbrecht DGJ; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Valderrama BP; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain., van der Noort V; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl.
Jazyk: angličtina
Zdroj: BJC reports [BJC Rep] 2024 Oct 23; Vol. 2 (1), pp. 84. Date of Electronic Publication: 2024 Oct 23.
DOI: 10.1038/s44276-024-00104-3
Abstrakt: Background: Anti-PD-(L)1 agent are approved as first- and second-line treatment options in advanced urothelial cancer (UC), but information about long-term survival is scarce. There is a need for prognostic factors, as these may help in the decision-making concerning anti-PD-(L)1 in patients with UC. Here, we examined long-term survival following anti-PD-(L)1 in advanced UC and assessed clinical factors for their correlation with survival.
Methods: We collected data from patients with advanced UC treated with anti-PD-(L)1 between 2013 and 2023. Overall- and progression-free survival (OS, PFS) were determined using the Kaplan-Meier method. Independent variables were analysed by uni- and multivariate Cox regression for their association with OS and PFS.
Results: Survival analyses included 552 patients. Patient characteristics in our cohort were consistent with those of a typical advanced UC population. After median follow-up of 49 months, five-year OS and PFS rates were 16.0% and 6.9% respectively. The absence of visceral and/or bone metastases and elevated C-reactive protein level, gamma-glutamyltransferase level and neutrophil-to-lymphocyte ratio were identified as favourable prognostic factors for OS.
Conclusions: A selected subset of patients with advanced UC may experience long-term clinical benefit from anti-PD-(L)1 treatment. We identified prognostic factors that might be used for risk assessment and clinical trial stratification.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: